These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35723271)

  • 1. Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine.
    Vu DM; Vu DTB; Do TTT; Olmsted AE; Dao BH; Thai TT; Nguyen CL; Le NTT; Le TA; Bui HTT; Pham TN; Moore MR
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S174-S181. PubMed ID: 35723271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines.
    Alroqi F; Barhoumi T; Masuadi E; Nogoud M; Aljedaie M; Abu-Jaffal AS; Bokhamseen M; Saud M; Hakami M; Arabi YM; Nasr A
    J Infect Public Health; 2024 Apr; 17(4):704-711. PubMed ID: 38479067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala.
    Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V
    Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
    Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
    Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
    Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
    Front Immunol; 2021; 12():779212. PubMed ID: 34899739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
    Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
    Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2.
    Chau NVV; Nguyet LA; Dung NT; Quang VM; Truong NT; Toan LM; Hung LM; Man DNH; Khoa DB; Phong NT; Ngoc NM; Thao HP; Ty DTB; Thanh PB; Ny NTH; Thanh LK; Thuy CT; Anh NT; Hong NTT; Nhu LNT; Yen LM; Thwaites G; Thanh TT; Tan LV;
    Am J Trop Med Hyg; 2023 Jan; 108(1):137-144. PubMed ID: 36450229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
    Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
    Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers.
    Jeong S; Lee N; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Kim HS
    Front Immunol; 2022; 13():859019. PubMed ID: 35720318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Results of Five SARS-CoV-2 Antibody Assays before and after the First and Second ChAdOx1 nCoV-19 Vaccinations among Health Care Workers: a Prospective Multicenter Study.
    Jeong S; Lee N; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Jung EJ; Woo H; Seo YB; Park JJ; Kim HS
    J Clin Microbiol; 2021 Nov; 59(12):e0178821. PubMed ID: 34613799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status.
    Lumley SF; Rodger G; Constantinides B; Sanderson N; Chau KK; Street TL; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Warren F; Peck LJ; Ritter TG; de Toledo Z; Warren L; Axten D; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Chand M; Crook DW; O'Donnell AM; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Hopkins S; Walker TM; Stoesser NE; Matthews PC; Jeffery K; Eyre DW;
    Clin Infect Dis; 2022 Apr; 74(7):1208-1219. PubMed ID: 34216472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.